Recent molecular advances have identified a novel, clinically aggressive subgroup of undifferentiated round cell sarcomas defined molecularly by oncogenic fusion of the gene, CIC, and either DUX4 or its paralog, DUX4L, herein termed CIC-DUX sarcomas. Morphologically, CIC-DUX sarcomas are round cell sarcomas with high-grade nuclear features, including vesicular chromatin and nucleoli, patchy clear cell foci, myxoid change, and necrosis. Here, we studied a cohort of 10 cases, including 6 newly identified cases, 2 with paired metastases. Given our prior observation of trisomy 8 in these tumors, we assayed for amplification and expression of MYC (cMyc) and representative downstream targets. Trisomy 8 was detected in 5/7 testable cases, with further amplification of MYC locus in 6/7 testable cases and immunohistochemical expression of MYC in 10/10. The canonical MYC transcriptional target, p21, but not MTDH, was differentially expressed compared with Ewing sarcomas. Given prior observation of induction of ETS-family transcription factors by the fusion oncoprotein, we assayed and identified highly prevalent positivity for ERG (9/10) and FLI1 (8/8). These findings are cautionary regarding use of these immunostains in prospective case workup, whereas the prevalent MYC amplification may represent a therapeutically targetable oncogenic pathway in CIC-DUX sarcomas.
Recent molecular efforts have identified that a significant subset 1 of undifferentiated small round cell sarcomas harbor a recurrent translocation, involving the gene, CIC (capicua transcriptional suppressor), on chromosome 19, fused with one of two poorly understood genes, either DUX4 (double homeobox 4), on chromosome 4 or its paralog, DUX4L (double homeobox 4-like), on chromosome 10, resulting in either CIC-DUX4, t(4;19)(q35;q13) or CIC-DUX4L, t(10;19)(q26;q13) fusions. These sarcomas, originally characterized in the pediatric population, [2] [3] [4] [5] have been found to occur over a wide age range, though they arise predominantly in young adults. [6] [7] [8] [9] [10] We recently reported four undifferentiated round cell sarcomas harboring CIC-DUX4 fusions, 11 which, together with reported CIC-DUX4L 6 cases, we term 'CIC-DUX sarcomas'. These tumors demonstrated clinical behavior at least as aggressive as Ewing sarcomas, with all four patients expiring from disease within 18 months. The tumors had reproducible histomorphology including high-grade nuclear features (vesicular chromatin, moderate nuclear pleomorphism, and prominent nucleoli), lobular growth pattern, geographic necrosis, round cell cytomorphology, patchy clear cell areas, and distinctive foci of myxoid change.
Given the limited experience with these tumors, we sought to characterize an expanded cohort to study CIC-DUX sarcoma histomorphology. As in vitro data suggest that the fusion oncoproteins of these sarcomas may induce expression of ETS-family proto-oncogenes, 8 and as we and others 12 have noted ERG or FLI1 expression in individual cases, we studied expression of these markers in light of the differential with Ewing sarcoma. Finally, proceeding from our observation of polysomy for chromosome 8 in CIC-DUX cases, 11 we tested for expression and amplification of the frequently amplified chromosome 8 proto-oncogene, MYC (c-Myc), as well as downstream transcriptional targets.
Materials and methods

Cohort
Under IRB-approved protocols, retrospective searches were performed using institutional pathology databases for small round cell sarcomas, predominantly arising in the soft tissue, which had been previously unclassifiable. Four of the cases identified were previously reported. 11 Six additional cases were identified at the University of Michigan, Cleveland Clinic, and Cedars-Sinai Medical Center. Demographic, pathologic, and clinical follow-up data were tabulated for each case. A previously constructed 13 tissue microarray of 70 primary and metastatic lesions of 45 cases of Ewing sarcoma (24 classic skeletal, 19 extraskeletal, 2 metastases only) was analyzed for comparison purposes.
Molecular Testing
We have previously detailed our molecular assays used to establish diagnosis in CIC-DUX sarcomas. Briefly, to assay for rearrangement at the CIC locus, two dual color interphase fluorescence in situ hybridization (FISH) strategies were used. The first used rhodamine labeled BAC clone RP11-569M1, spanning the CIC gene at 19q13, and fluoresceinlabeled RP11-46I12, a centromeric control marker for chromosome 19. The second used conventional 'break apart' probes made from BAC clones RP11-317E13 (flanking, centromeric, Cy5 labeled) and RP11-778C1 (flanking, telomeric, fluorescein labeled) to CIC. For the first probe set, tumors showing 410% nuclei with three rhodamine signals (CICspanning target split) and two fluorescein signals (centromeric control) were considered positive for rearrangement. For the latter strategy, tumors with 410% of nuclei with split green/red signals were considered positive. A final three color dual fusion strategy was used to assay for fusion of either DUX4 or DUX4L and CIC, using probes from RP11-778C1 telomeric to CIC (fluorescein labeled), RP11-521G19, centromeric to DUX4 (rhodamine labeled), and RP11-108K14, centromeric to DUX4L (AQUA labeled). For MYC amplification and chromosome 8 polysomy testing, commercially available two color probes for the MYC locus at 8q24 and CEN-8 were purchased and used per manufacturer instructions (Poseidon Probes, Veridex, Raritan, NY, USA). Our nested RT-PCR assay for the CIC-DUX4 fusion transcript was used as previously reported, 11 using a primer design and control plasmid developed by Kawamura-Saito et al. 8 Two cases had also been tested by FISH at Memorial Sloan Kettering Cancer Center, providing additional confirmation of the diagnosis.
Immunohistochemical Analysis
Immunostain for ERG was performed as described previously using a ready-to-use, prediluted monoclonal antibody against ERG, clone EPR3864 (Ventana Medical Systems, Tucson, AZ) using a Ventana XT autostainer as detailed previously. [13] [14] [15] Immunohistochemical staining for FLI1 (Neomarkers, Fremont, CA, USA), p21/WAF1 (DAKO, Carpinteria, CA, USA) MTDH, (Millipore, Billerica, MA, USA), and CD99 (DAKO) was performed on a DAKO Autostainer (DAKO) using DAKO LSAB þ (FLI1 and MTDH) or Envision þ (p21) and diaminobenzadine as chromogen. Microwave citric acid epitope retrieval was used for FLI1, MTDH, and CD99 prior to staining. Microwave epitope retrieval in 10 mMTris/1 mM EDTA pH9 was used for p21. MYC rabbit monoclonal (Y69, Abcam) was used at 1/50 dilution, in buffer CC1 for 36 min (pH 8.5 HIER buffer at 95 1C), with 32 min primary incubation at 37 1C. Appropriate negative (no primary antibody) and positive controls were stained in parallel with each set of antibodies studied.
Immunohistochemical scoring was performed (SCS, DGT, RMP) using two scoring systems. A conventional 0-3 þ by proportion (0, negative; 1 þ , focal; 2 þ multifocal; 3 þ diffuse) was used for scoring whole-tissue sections stained utilizing antibodies used in our routine clinical practice (ERG, FLI1, MYC, CD99). For scoring the TMA format used for testing the MYC targets p21/WAF1 and MTDH, we used an Allred score (0-8, 0-5 proportion score summed with a 0-3 intensity score) 16 for comparison between expression of these targets in CIC-DUX sarcomas and Ewing sarcomas. Specifically, for the Allred score intensity and proportion, both contribute to an overall score (0, none; 1, o1%; 2, 1-10%; 3, 10-33%; 4, 33-66%; and 5, 466% plus an intensity score of 0, none; 1, weak; 2, intermediate; and 3, strong). Distributions of ordinal Allred scores for p21 and MTDH were compared between CIC-DUX sarcomas and Ewing sarcomas by the Mann-Whitney U-test, with significance assumed at an alpha of 0.05.
Results
Cohort
The final cohort included three males and seven females, with age range of 20-43 years, median 35 years. The tumors ranged in size from 3 to 14 cm (median 6 cm) and arose predominantly in soft tissues of the extremities, with half arising in the soft tissues of the lower extremities. The gene fusions identified were t(4;19)/CIC-DUX4 in 8/10 cases, and t(10;19)/CIC-DUX4L in 2/10 cases, the latter both among the new cases. Of six new cases, follow-up was available for five, where metastasis was noted in 4/5, one demise at 11 months, one case alive with disease progressing on palliative chemotherapy, and three cases showing no evidence of disease at up to 48 months after diagnosis, two of which show no evidence of disease after metastectomy. Table 1 summarizes the clinicopathologic, molecular, and treatment/outcome parameters of these cases.
Morphology
We prospectively evaluated morphological features described previously as characteristic of CIC-DUX sarcomas, 11, 12 particularly the distinctive myxoid change and patchy clear cell areas, but also including the lobular growth pattern, necrosis, high-grade nuclear features, and presence and extent of spindled cytomorphology. Compared with Cases 1-4 reported previously, 11 Cases 5-10 showed relatively more extensive myxoid stromal change in 3/6. In Case 9, this morphology resulted in resemblance to extraskeletal myxoid chondrosarcoma or myoepithelioma. Clear cell change was variable, present in 5/6 primary lesions, whereas the one case that lacked clear cell change showed this feature in its metastasis. Foci of spindled cellular morphology were identified in 5/6 cases. Metastatic deposits were available for review for Cases 7 and 9; both showed a degree of dense, sheetlike growth exceeding that of the primary tumor. Figures 1 and 2 illustrate the morphological features seen, whereas Table 2 summarizes the morphological observations by case.
Immunophenotype and Genotype
Both the cases previously reported 11 and those newly identified were studied by immunohistochemistry (IHC) for expression of Ewing sarcoma-associated ( Figure 2j-l) . ERG was positive in 9/10 cases; FLI1 was positive in 8/8 cases. Overall, FLI1 positivity was more extensive and intense than that of ERG. The patterns of FLI1 and ERG are demonstrated in Figure 3 ; Table 3 details the immunophenotype by case. We previously observed trisomy 8 in two CIC-DUX cases where karyotyping was performed in routine clinical workup. 11 Among the six newly identified cases, cytogenetic data were only available for one additional case, a t(10;19) CIC-DUX4L case, which also showed trisomy 8. Given the known locus of MYC (c-Myc) on chromosome 8, we hypothesized that this oncogene might be of significance in CIC-DUX sarcomas. Immunohistochemical MYC expression was positive, mostly diffuse, in 10/10 cases. On the basis of this observation, we tested for amplification of the MYC locus by FISH, using probes spanning the MYC locus to evaluate copy number, and centromeric controls for chromosome 8 as a surrogate for ploidy. Trisomy for chromosome 8 was seen in 5/7 cases successfully tested, confirming the cytogenetic observation of trisomy 8 in one of the two previous cases (the hybridization was unsuccessful in the other). Amplification of the MYC locus, present as multiple additional copies, was identified in six of seven cases; two cases harbored amplification without chromosome 8 polysomy. Figure 4 shows representative MYC FISH and IHC findings; Table 3 summarizes immunophenotypic and FISH results by case.
Two established transcriptional targets of MYC signaling include Metadherin (AEG-1/Astrocyte Elevated Gene 1/Lyric) encoded at MTDH 17 and p21 (WAF1/CIP1) encoded at CDKN1A. 18 To study how the pattern of expression of these transcriptional targets in CIC-DUX sarcomas compares with Ewing sarcoma, we used a tissue microarray, constructed of Ewing sarcoma cases described previously. 13 Comparing semiquantitative Allred IHC scores 16 between CIC-DUX and Ewing sarcoma cases, we found that MTDH was expressed similarly (P ¼ 0.20), whereas p21 expression was significantly greater in the CIC-DUX cases (Po0.001) (see Figure 5 ).
Discussion
Recent molecular advances, especially next generation sequencing, have allowed identification of a number of subtypes of undifferentiated round cell and spindle cell sarcomas as defined by the 2013 WHO classification, 19 several of which lack EWSR1 gene rearrangement 12 and harbor characteristic alternative genomic alterations. Among recently recognized molecular subtypes of these undifferentiated sarcomas are tumors harboring CIC-DUX4 and CIC-DUX4L fusions, 6,11 which may constitute a substantial subset of such cases. 6 The distinctive features described by others, 2,3,5-8 in our prior cohort, 11 and replicated herein, lead us to suggest that these tumors be regarded as a distinct entity, defined not only by their distinctive molecular but also by reproducible histopathologic characteristics.
We would argue, as have others, 12 that diagnostic recognition of this entity as a high-risk malignancy From the standpoint of histomorphology, our observations on newly collected cases confirm observations from our previously reported cohort 11 and further establish characteristic, if variable, histomorphological features. A distinctive and prevalent feature is the observation of myxoid change, which in some of the newly identified cases was extensive, resulting in some resemblance to soft tissue myoepithelial carcinoma or extraskeletal myxoid chondrosarcoma. Characteristic also is the patchy clear cell change, which ranged from focal to diffuse in the newly identified cases, apparent only in the metastasis of one case. We also observed areas showing spindled to fusiform cytomorphology, often associated with areas of myxoid stromal change, similar to that seen in myxoid synovial sarcoma, 21 which were not observed in our prior series. The nodular growth of sheets of high-grade cells with attenuated cytoplasm separated by fibrous septae is a consistent architectural feature. Nuclear morphology, including a vesicular nuclear appearance, often with readily identified nucleoli and mild-to-moderate pleomorphism, is distinctive as compared with Ewing sarcoma. For that matter, rosette formation was not identified in any case evaluated. Prominent 
Abbreviations: Chr., chromosome; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; NC, non-contributory technical failure; ND, tissue insufficient-not done. geographic necrosis, often striking at low power, is a feature of the majority of cases; a rim of preserved tumor cells is often present around tumoral vasculature. Single-cell necrosis, imparting a 'starry sky' appearance, 12 was observed in these cases, as well. The diagnosis of Ewing sarcoma of bone or extraskeletal soft tissues is clinical and morphological, assisted by adjunctive molecular studies. CD99 IHC, when positive with a diffuse membranous pattern, is supportive of a diagnosis of Ewing sarcoma. Although most cases of CIC-DUX sarcoma demonstrated some CD99 immunoreactivity, in our experience, the CD99 pattern in CIC-DUX sarcomas is different from that seen in Ewing sarcoma cases. We, 11 and others 2,5-8 have observed mostly focal to patchy staining, though our single CIC-DUX4L case with diffuse CD99 (although not membranous) is cautionary and correlates a with a few other reported CIC-DUX cases that showed diffuse CD99 2, 3, 6 immunoreactivity.
More specific to the molecular abnormalities seen in Ewing sarcomas is IHC for two members of the ETS family of proto-oncogenic transcription factors, ERG, and FLI1. FLI1 IHC has been used as supportive evidence of Ewing sarcoma. 22 More recently, a monoclonal antibody against the closely related ETS family member, ERG, in widespread clinical use as a specific marker of prostatic adenocarcinoma 23, 24 and benign and neoplastic endothelium, 25 has shown cross reactivity with FLI1, and hence promise in diagnosis of Ewing sarcomas harboring FLI1 13 or ERG rearrangement, 26 depending on the dilution used. Although nuclear pleomorphism, nucleoli, geographic necrosis, spindling, clear cell change, and, especially, myxoid change are not typically seen in Ewing sarcoma, the two tumors may be difficult to distinguish in small samples. We observed positivity for FLI1 and/or ERG in essentially all of the CIC-DUX sarcomas studied, a finding similar to that expected in Ewing sarcoma, and therefore, a relevant and significant pitfall in diagnosis.
The observations of FLI1 and ERG immunoreactivity in our CIC-DUX4 sarcomas corroborate those noted in previous cases, 4, 6 as well as a very recent report that these sarcomas very frequently coexpress nuclear WT1 and ETS-family factors, 27 the former overlapping with the immunophenotype of desmoplastic small round cell tumor. Although such immunostains may have a role for triage of limited biopsy samples, we regard confirmation of a morphological diagnosis of Ewing sarcoma of bone or extraskeletal soft tissue (or exclusion of Ewing in a possible CIC-DUX case) to be best accomplished through molecular testing for EWSR1 rearrangement. Also notable are recently reported findings of strong induction of expression of other ETSfamily transcription factors, including ETV1, ETV4 (PEA3), and ETV5, in gene expression profiling studies. 8, 27 This observation implies testable hypotheses regarding the oncogenic mechanism of the CIC-DUX fusion transcripts. We are exploring the potential for use of these additional ETS members as diagnostic adjuncts by RNA in situ hybridization. 28 On the basis of observation of additional copies of chromosome 8 in the karyotypes in three of our cases, we hypothesized that MYC amplification might be important in the development of CIC-DUX sarcomas. We observed polysomy for chromosome 8 in the majority of our cases, with amplification of the MYC locus in 6/7 and MYC protein overexpression in all cases tested. Although this is not entirely surprising given the high prevalence of MYC amplification or overexpression in high-grade carcinomas, lymphomas, and sarcomas, [29] [30] [31] [32] [33] this observation may have potential therapeutic implications, in light of a number of emerging strategies to target this pathway. 29 The differential expression of two well-studied MYC targets, p21 18 and MTDH 17 in CIC-DUX sarcomas as compared with Ewing sarcomas is also worth noting. Expression of MTDH (Metadherin/ AEG-1/Astrocyte Elevated Gene 1/Lyric), which we found to be a shared and prevalent feature of both CIC-DUX sarcomas and Ewing sarcoma, may be important mechanistically and as a therapeutic target. A growing body of literature implicates MTDH as a specific mediator of lung metastasis in breast adenocarcinoma, 34 a provocative finding in light of the frequent lung metastasis among the CIC-DUX sarcomas (and, for that matter, among Ewing sarcomas). Expression of MTDH has been recently noted as a poor prognostic factor in Ewing sarcoma and other sarcomas, 35, 36 and proposed as a targetable cell surface marker. 37 In contrast, we found that expression of p21 was significantly greater in CIC-DUX sarcomas. Though only a subset of nuclei in these tumors was positive for p21, this observation identifies another difference in cell signaling between CIC-DUX and Ewing sarcomas despite their shared expression of, and implicitly, shared dependency on, oncogenic ETS transcription factor signaling.
In summary, based on the findings of an expanded set of CIC-DUX sarcoma cases, we have validated prior observations of characteristic demographic features, aggressive clinical behavior, and histomorphology. Recognition of this entity is clinically relevant, and we highlight prevalent ERG and FLI1 positivity as an important consideration during diagnostic workup. Finally, prevalent MYC amplification with differential expression of downstream targets may represent a therapeutically targetable oncogenic pathway in CIC-DUX sarcomas, but additional studies are needed.
